Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
Authors
Keywords
-
Journal
ACTA DIABETOLOGICA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-24
DOI
10.1007/s00592-021-01681-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
- (2020) Benedetta Maria Bonora et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat
- (2019) Nandini Manne et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Renal effects of SGLT2 inhibitors
- (2019) Josselin Nespoux et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Mechanisms of Renal Fibrosis
- (2018) Benjamin D. Humphreys Annual Review of Physiology
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression
- (2018) Noha A. T. Abbas et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
- (2017) Xiaoxin X. Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
- (2017) Vance B. Matthews et al. JOURNAL OF HYPERTENSION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis
- (2017) William L. Baker et al. Journal of the American Heart Association
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Angiotensin Type-2 (AT-2)-Receptor activation reduces renal fibrosis in cyclosporine nephropathy: Evidence for blood-pressure independent effect.
- (2016) G. Castoldi et al. BIOSCIENCE REPORTS
- Different regulation of miR-29a-3p in glomeruli and tubules in an experimental model of angiotensin II-dependent hypertension: potential role in renal fibrosis
- (2016) Giovanna Castoldi et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review
- (2016) Cecilia Beatrice Chighizola et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive MedicationNovelty and Significance
- (2016) Giuseppe Mancia et al. HYPERTENSION
- A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
- (2016) Yui Takeshige et al. HYPERTENSION RESEARCH
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
- (2016) Yanling Zhang et al. PLoS One
- Overview of the cellular and molecular basis of kidney fibrosis
- (2014) Allison A. Eddy Kidney International Supplements
- Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats
- (2013) Jan Mulder et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Annexin A1 protein attenuates cyclosporine-induced renal hemodynamics changes and macrophage infiltration in rats
- (2011) Leandro Pires Araujo et al. INFLAMMATION RESEARCH
- Intermittent Therapy with 1,25 Vitamin D and Calcitonin Prevents Cyclosporin-Induced Alveolar Bone Loss in Rats
- (2010) Luís C. Spolidorio et al. CALCIFIED TISSUE INTERNATIONAL
- Calcineurin Inhibitor Nephrotoxicity
- (2009) M. Naesens et al. Clinical Journal of the American Society of Nephrology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started